Catalog No.
Product Name
Application
Product Information
Citations
-
Src-FAK-Paxillin Inhibitor
JP-153 is a Src-FAK-Paxillin signaling inhibitor that specifically targets the Src-dependent phosphorylation of paxillin at tyrosine 118, leading to downstream inhibition of Akt activation at serine 473. This compound effectively reduces VEGF-induced migration and proliferation in retinal endothelial cells, making it a valuable tool for studying neovascular eye diseases. Researchers can utilize JP-153 to explore the molecular mechanisms underlying angiogenesis and potential therapeutic interventions. -
Src inhibitor
Tirbanibulin Mesylate (KX2-391 Mesylate) is an inhibitor of Src that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. -
Src/c-Abl inhibitor
1-Naphthyl PP1 hydrochloride is a selective inhibitor of src family kinases v-Src and c-Fyn as well as the tyrosine kinase c-Abl (IC50 values are 1.0, 0.6, 0.6, 18 and 22 μM for v-Src, c-Fyn, c-Abl, CDK2 and CAMK II respectively). -
Src kinase inhibitor
7-Hydroxychromone is a Src kinase inhibitor with an IC50 of <300 μM. -
fMLP inhibitor
Larixol is an fMLP inhibitor that also suppresses key signaling pathways involved in immune regulation, including Src kinase, ERK1/2, p38, and AKT phosphorylation. It disrupts the interaction between the βγ subunit of the fMLP receptor Gi protein and downstream effectors, thereby inhibiting fMLP-induced respiratory burst. Larixol effectively inhibits fMLP (0.1 μM)-induced superoxide anion production (IC50: 1.98 μM), cathepsin G release (IC50: 2.76 μM), and neutrophil chemotaxis. It mitigates neutrophil hyperactivation and helps reduce inflammation and tissue damage. Additionally, Larixol derivatives have shown inhibitory activity against TRPC6 functional mutants associated with focal segmental glomerulosclerosis (FSGS). -
multi-kinase PROTAC degrader
SB1-G-187 is a multifunctional PROTAC designed as a multi-kinase degrader, capable of inducing the selective degradation of multiple kinase targets through the ubiquitin–proteasome system. In addition to its targeted degradation activity, SB1-G-187 features an alkyne functional group, enabling its use as a click chemistry reagent. It can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAC) with azide-containing molecules, allowing for versatile applications in chemical biology, such as probe development, conjugation, and target identification. -
PROTAC c-Src kinase degrader
DAS-5-oCRBN is a selective and potent PROTAC degrader of c-Src kinase, acting through CRBN-mediated ubiquitination. It effectively reduces c-Src levels and inhibits proliferation in c-Src-dependent cancer cell lines, making it a useful tool for targeted protein degradation research. -
Src/Akt Inhibitor
Chrysotoxine is a dual inhibitor of the Src and Akt signaling pathways. It effectively suppresses cancer stem cell phenotypes by down-regulating the Src/Akt pathway, leading to reduced cell viability and increased apoptosis in H460 and H23 cancer cell lines, while sparing non-tumor cell lines. Due to its rapid excretion and low bioavailability in animal studies, Chrysotoxine serves as a valuable tool in cancer research, particularly for investigating therapies targeting cancer stem cells. -
Src Inhibitor
Si306 is a selective Src inhibitor known for its antitumor properties. It effectively reduces the phosphorylation of focal adhesion kinase (FAK) and downregulates the expression of epidermal growth factor receptor (EGFR), thereby inhibiting the invasion of human glioblastoma (GBM) cells. This compound is valuable for research focused on understanding Src-related signaling pathways and developing targeted cancer therapies. -
Src Kinase Inhibitor
SKS-927 is a potent Src kinase inhibitor with an IC50 value of 3.9 nM, demonstrating significant inhibition of Src-transformed cell proliferation in rat fibroblasts, with an IC50 of 73 nM. Additionally, SKS-927 shows activity against EGFR at an IC50 of 720 nM. This compound is applicable in research focused on cancer and osteoporosis, making it a valuable tool for investigating therapeutic pathways in these conditions. -
Src Inhibitor
β-Hydroxyisovalerylshikonin is a natural product derived from Lithospermum erythrorhizon, functioning as a potent Src inhibitor. It exhibits significant inhibitory activity against protein tyrosine kinases, with IC50 values of 0.7 μM for EGFR and 1 μM for the v-Src receptor. This compound demonstrates broad anticancer activity, particularly inducing cell death in various tumor cell lines, most notably in NCI-H522 and DMS114 cells, making it a valuable tool for cancer research applications. -
SRC Stimulator
(E/Z)-MCB-613 is a pan-Steroid Receptor Coactivator (SRC) stimulator that enhances SRC activity in cancer cells. This leads to the overstimulation of reactive oxygen species (ROS) production, resulting in cell stress and apoptosis through a mechanism known as paraptosis. (E/Z)-MCB-613 serves as a cytotoxic agent with significant implications for cancer research, particularly in studies focusing on targeted cancer therapies and mechanisms of cell death. -
EphB4/Src Kinase Inhibitor
AZ12672857 is a potent inhibitor of EphB4 and Src kinases, demonstrating an IC50 of 1.3 nM for EphB4. This compound significantly inhibits the proliferation of c-Src transfected 3T3 cells with an IC50 of 2 nM and autophosphorylation of EphB4 in CHO-K1 cells with an IC50 of 9 nM. AZ12672857 can be utilized in studies investigating signaling pathways related to cancer and cell growth regulation. -
Src
Canine Secretin is an endocrine hormone that primarily targets the Src kinase pathway. It stimulates the secretion of bicarbonate-rich pancreatic fluids and regulates gastric chief cell function, as well as paracellular permeability in canine gastric monolayers. This reagent is valuable for research applications involving gastrointestinal physiology and pancreatic function in canines. -
SRC-1 Degrader/PROTAC
ND1-YL2 is a PROTAC that selectively targets and degrades SRC-1 through the N-degron pathway. This compound has demonstrated significant inhibition of cancer cell invasion and migration both in vitro and in vivo. ND1-YL2 serves as a valuable tool in cancer research, providing insights into the role of SRC-1 in tumor progression and metastasis. -
SRC-3 Inhibitor
SI-2 hydrochloride is a potent inhibitor of SRC-3, a transcription co-regulator involved in various signaling pathways. This compound displays favorable pharmacokinetic properties and reduced toxicity, making it suitable for in vivo studies. SI-2 hydrochloride is valuable for research related to cancer biology, endocrine signaling, and other conditions where SRC-3 plays a critical role. -
AKT1/SRC/STAT3/EGFR Binder
(+)−Theta-cypermethrin is a stereoisomer of cypermethrin that functions as a selective binder to AKT1, SRC, STAT3, and epidermal growth factor receptor (EGFR). This compound is known to penetrate the blood-brain barrier, leading to alterations in the amplitude of delayed rectifier potassium channel currents and significant shifts in the activation and inactivation curves at elevated concentrations. Additionally, (+)-Theta-cypermethrin induces abnormal electrical activity in rat hippocampal neurons and is associated with chronic respiratory system damage and neurotoxicity. It serves as a valuable tool for research into signal transduction pathways and neuropharmacology. -
VEGFR/Tyrosine Kinase Src Inhibitor
TG 100948 is a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and tyrosine kinase Src. This compound demonstrates significant biological activity by reducing retinal edema and retinal thickening, as well as eliminating bullous edema cysts in rat models of ischemic retinal vein occlusion. TG 100948 is valuable for research into the pathophysiology and potential treatments of ischemic retinal vein occlusion. -
Src tyrosine kinase inhibitor
Src Inhibitor 1 is a potent and selective dual site Src tyrosine kinase inhibitor with IC50 values of 44 nM for Src and 88nM for Lck. - MLR 1023 is a selective allosteric activator of Lyn kinase (EC50 = 63 nM)
-
Src Inhibitor
PP1 is a potent inhibitor of Src-family tyrosine kinases. Inhibits p56lck and p59fynT (IC50 values are 5 and 6 nM respectively). Displays > 8000-fold selectivity over ZAP-70 and JAK2. Also moderately inhibits p38, CSK, PDGF receptors, RET-derived oncoproteins, c-Kit and Bcr-Abl -
IGF-1R, Aurora, FGFR, ABL, SRC inhibitor
XL228 is a protein kinase inhibitor targeting IGF1R, the AURORA kinases, FGFR1-3, ABL and SRC family kinases. XL228 is an Aurora A inhibitor (IC50, f3 nmol/L) that has shown potent biochemical activity against ABL1 (Ki, 5 nmol/L), as well as the BCR-ABL1 T315I (Ki, 1.4 nmol/L) kinases. -
Src inhibitor
KX2-391 is a novel non-ATP competitive substrate-pocket directed SRC inhibitor.
-
Src inhibitor
KX2-391 2Hcl is the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. - Scutellarin, a main active ingredient extracted from Erigeron breviscapus (Vant.) Hand-Mazz, has been wildly used to treat acute cerebral infarction and paralysis induced by cerebrovascular diseases.
-
Src inhibitor
PD 166285 is a potent inhibitor of the tyrosine kinases c-Src, Flg (fibroblast growth factor receptor 1, FGFR1).
